Clinical Trials Directory

Trials / Conditions / Newly Diagnosed

Newly Diagnosed

22 registered clinical trials studyying Newly Diagnosed — 9 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingA Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible
NCT07070960
Xuzhou Medical UniversityN/A
Not Yet RecruitingCAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?
NCT07070934
Xuzhou Medical UniversityPhase 2
RecruitingComparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/
NCT06532552
The First Affiliated Hospital of Soochow UniversityPhase 2
RecruitingTreatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
NCT06409702
The First Affiliated Hospital of Soochow UniversityPhase 4
RecruitingZanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
NCT06553352
The First Affiliated Hospital of Xiamen UniversityPhase 2
Active Not RecruitingZanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic
NCT06547944
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1
RecruitingClinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
NCT05833893
Chinese PLA General HospitalPhase 2
RecruitingStudy of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05673057
Molecular Partners AGPhase 1 / Phase 2
UnknownShared Decision Making on Care Pathways and CAMs: A Pilot Study
NCT05388734
University Hospital, GrenobleN/A
CompletedNon-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Tr
NCT05284591
iOMEDICO AG—
UnknownZanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL
NCT05287984
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2
RecruitingVenetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic
NCT05566054
The First Affiliated Hospital of Soochow UniversityPhase 2
UnknownEfficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML
NCT04254640
Sun Yat-sen UniversityPhase 2
TerminatedPonatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL
NCT04554459
Institute of Hematology and Blood Transfusion, Czech RepublicPhase 2
UnknownVRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
NCT03641456
Sun Yat-sen UniversityPhase 2
Active Not RecruitingSelinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Gl
NCT04216329
National Cancer Institute (NCI)Phase 1
CompletedBlinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)
NCT04554485
Institute of Hematology and Blood Transfusion, Czech RepublicPhase 2
Active Not RecruitingA Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Respo
NCT03522246
pharmaand GmbHPhase 3
RecruitingIdentify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and R
NCT02677064
Memorial Sloan Kettering Cancer Center—
Active Not RecruitingOlaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Ba
NCT01844986
AstraZenecaPhase 3
CompletedEffect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic P
NCT01147627
Sun Yat-sen UniversityN/A
CompletedLong Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment
NCT00632255
Imperial College London—